TABLE 3.
Clinical and laboratory data of the patients without dose change after preparation switch (n=12)
| Colchicum Dispert | Colchicine Opocalcium | p | |
|---|---|---|---|
| Duration of treatment (months) | 61.51±37.74* | 19.76±15.34* | <0.001 |
| Dose (mg/day) | 1.71±0.45* | 1.71±0.45* | |
| Number of attacks at the last 6 months | 5.22±2.09* | 1.17±1.66* | <0.001 |
| Average duration of FMF attacks (hours) | 48 (48–51)** | 24 (24–30)** | <0.001 |
| EILP (attack-free period) | 7.04±1.35* | 2.29±1.90* | <0.001 |
| FMF severity score | 9.26±1.88* | 5.92±2.08* | <0.001 |
| Hb (g/dL) | 12.26 (12.27–12.33)** | 12.1 (12.10–12.11)** | 0.045 |
| WBC (/mm3) | 6,560 (6,560–6,590**) | 6,510 (6,510–6,583)** | 0.798 |
| Plt (103/mm3) | 249 (249–249.37) | 284 (287.75) | 0.540 |
| NLR (Neu/Lym) | 1.07 (1.07–1.09)** | 1.07 (1.04–1.07)** | <0.001 |
| MPV (fL) | 8.10 (8.10–8.11)** | 6.70 (6.70–6.74)** | 0.046 |
| ALT (U/L) | 43 (42–43)** | 45 (41.37–45)** | <0.001 |
| CRP (mg/L) | 1.54 (1.54–1.64)** | 0.03 (0.03–0.17)** | 0.01 |
| ESR (mm/h) | 44 (41.75–44.00)** | 23 (21.25–23.00)** | <0.001 |
*
Mean±standard deviation;
**
Median (25th to 75th percentile).
ALT: Alanine Aminotransferase, CRP: C-Reactive Protein, EILP: Exercise-Induced Leg Pain (Visual Analog Scale Score), ESR: Erythrocyte Sedimentation Rate, FMF: Familial Mediterranean Fever, Hb: Hemoglobin, MPV: Mean Platelet Volume, NLR: Neutrophil-to-Lymphocyte Ratio, Plt: Platelet Count, WBC: White Blood Cell Count.